Human CLEC9A antibodies deliver NY-ESO-1 antigen to CD141+dendritic cells to activate naïve and memory NY-ESO-1-specific CD8+T cells

Kelly-Anne Masterman, Oscar L Haigh, Kirsteen M Tullett, Ingrid M. Leal-Rojas, Carina Walpole, Frances E. Pearson, Jonathon Cebon, Christopher Schmidt, Liam O'Brien, Nikita Rosendahl, Ghazal Daraj, Irina Caminschi, Eric H. Gschweng, Roger P. Hollis, Donald B. Kohn, Mireille H Lahoud, Kristen J. Radford

Research output: Contribution to journalArticleResearchpeer-review

11 Citations (Scopus)


Background Dendritic cells (DCs) are crucial for the efficacy of cancer vaccines, but current vaccines do not harness the key cDC1 subtype required for effective CD8+T-cell-mediated tumor immune responses. Vaccine immunogenicity could be enhanced by specific delivery of immunogenic tumor antigens to CD141+DCs, the human cDC1 equivalent. CD141+DCs exclusively express the C-type-lectin-like receptor CLEC9A, which is important for the regulation of CD8+T cell responses. This study developed a new vaccine that harnesses a human anti-CLEC9A antibody to specifically deliver the immunogenic tumor antigen, NY-ESO-1 (New York esophageal squamous cell carcinoma 1), to human CD141+DCs. The ability of the CLEC9A-NY-ESO-1 antibody to activate NY-ESO-1-specific naïve and memory CD8+T cells was examined and compared with a vaccine comprised of a human DEC-205-NY-ESO-1 antibody that targets all human DCs. Methods Human anti-CLEC9A, anti-DEC-205 and isotype control IgG4 antibodies were genetically fused to NY-ESO-1 polypeptide. Cross-presentation to NY-ESO-1-epitope-specific CD8+T cells and reactivity of T cell responses in patients with melanoma were assessed by interferon γ(IFNÎ 3) production following incubation of CD141+DCs and patient peripheral blood mononuclear cells with targeting antibodies. Humanized mice containing human DC subsets and a repertoire of naïve NY-ESO-1-specific CD8+T cells were used to investigate naïve T cell priming. T cell effector function was measured by expression of IFNÎ 3, MIP-1β, tumor necrosis factor and CD107a and by lysis of target tumor cells. Results CLEC9A-NY-ESO-1 antibodies (Abs) were effective at mediating delivery and cross-presentation of multiple NY-ESO-1 epitopes by CD141+DCs for activation of NY-ESO-1-specific CD8+T cells. When benchmarked to NY-ESO-1 conjugated to an untargeted control antibody or to anti-human DEC-205, CLEC9A-NY-ESO-1 was superior at ex vivo reactivation of NY-ESO-1-specific T cell responses in patients with melanoma. Moreover, CLEC9A-NY-ESO-1 induced priming of naïve NY-ESO-1-specific CD8+T cells with polyclonal effector function and potent tumor killing capacity in vitro. Conclusions These data advocate human CLEC9A-NY-ESO-1 Ab as an attractive strategy for specific targeting of CD141+DCs to enhance tumor immunogenicity in NY-ESO-1-expressing malignancies.

Original languageEnglish
Article numbere000691
Number of pages11
JournalJournal for ImmunoTherapy of Cancer
Issue number2
Publication statusPublished - 30 Jul 2020


  • dendritic cells
  • immunogenicity
  • immunotherapy
  • melanoma
  • vaccine

Cite this